Sartorius Stedim BiotechCHIX:DIMP 84 OCF Margin % is 25.38% as of Mar. 2026, which is 17% above its 10-year median of 21.68. GuruFocus rates CHIX:DIMP with a GF Score™ of 84/100 and a GF Value™ of €207.88 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Sartorius Stedim Biotech ranks better than 88.59% on this metric.
The historical rank and industry rank for Sartorius Stedim Biotech's OCF Margin % or its related term are showing as below:
CHIX:DIMp'
s OCF Margin % Range Over the Past 10 Years
Min: 14.9 Med: 21.68 Max: 29.32
Current: 25.66
During the past 13 years, the highest OCF Margin % of Sartorius Stedim Biotech was 29.32%. The lowest was 14.90%. And the median was 21.68%.
CHIX:DIMp's OCF Margin % is ranked better than 88.59% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: 5.86
vs CHIX:DIMp: 25.66
Sartorius Stedim Biotech OCF Margin % Related Terms
Sartorius Stedim Biotech OCF Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:DIMP vs ISRG, BDX, MDLN: OCF Margin % Comparison
For the Medical Instruments & Supplies subindustry, Sartorius Stedim Biotech's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sartorius Stedim Biotech OCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sartorius Stedim Biotech's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Sartorius Stedim Biotech's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sartorius Stedim Biotech (CHIX:DIMP) has a OCF Margin % of 25.38% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Sartorius Stedim Biotech and its competitors. This is 17% above median its historical median of 21.68. Over the past decade, Sartorius Stedim Biotech's OCF Margin % has ranged from 14.90 to 29.32. According to the industry distribution chart, Sartorius Stedim Biotech ranks #93 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 11.4%.
Is Sartorius Stedim Biotech's OCF Margin % too high?
Sartorius Stedim Biotech's current OCF Margin % of 25.38% is 17% above median its 10-year median of 21.68. Over the past 10 years, this metric has ranged from a low of 14.90 to a high of 29.32. The Medical Devices & Instruments industry median OCF Margin % is 5.86. Sartorius Stedim Biotech's value of 25.38% is 333.1% above this industry median. Based on the distribution chart, Sartorius Stedim Biotech ranks #93 out of 815 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Sartorius Stedim Biotech has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius Stedim Biotech's OCF Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sartorius Stedim Biotech ranks #93 out of 815 companies for OCF Margin %. This places Sartorius Stedim Biotech in the top 11% of its industry — outperforming the majority of peers. The industry median OCF Margin % is 5.86. Sartorius Stedim Biotech's value of 25.38% is 333.1% above this benchmark. Historically, Sartorius Stedim Biotech's own OCF Margin % has ranged from 14.90 to 29.32 over the past decade. While the company's 10-year median is 21.68 vs. the industry median of 5.86, Sartorius Stedim Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Devices & Instruments company?
The median OCF Margin % among Medical Devices & Instruments companies is 5.86, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sartorius Stedim Biotech's current OCF Margin % of 25.38% is 333.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Sartorius Stedim Biotech and its competitors. For the Medical Devices & Instruments industry, the median OCF Margin % is 5.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sartorius Stedim Biotech's current OCF Margin % is 25.38%, which is 17% above median its own 10-year median of 21.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius Stedim Biotech stock overvalued right now?
Based on GuruFocus' analysis, Sartorius Stedim Biotech (CHIX:DIMP) is currently considered Modestly Undervalued. The stock's GF Value™ is €207.88, compared to a current price of €162.10 — trading 22% below its estimated fair value. The current OCF Margin % is 25.38%, which is 17% above median its 10-year median of 21.68 and 333.1% above the Medical Devices & Instruments industry median of 5.86. Sartorius Stedim Biotech's overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Sartorius Stedim Biotech (CHIX:DIMP), the current OCF Margin % is 25.38% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius Stedim Biotech (CHIX:DIMP) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius Stedim Biotech stock appears to be undervalued.
The current stock price of €162.10 is trading 22% below its estimated GF Value™ of €207.88.
GuruFocus considers Sartorius Stedim Biotech to be Modestly Undervalued.
Key valuation signals for CHIX:DIMP:
OCF Margin %: 25.38% (17% above median its 10-year median of 21.68)
GF Value™: €207.88 vs. price of €162.10 (22% below fair value)
Industry Position: 333.1% above the Medical Devices & Instruments median (#93 of 815)
No single metric tells the full story. See the CHIX:DIMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
84GF Score
Get the complete analysis for CHIX:DIMP
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:DIMP has been successfully added to your 
